TEAD inhibitors and uses thereof

1. A method for treating a cancer in a patient, comprising administering to the patient a compound of Formula I′:

or a pharmaceutically acceptable salt thereof, wherein:

L 1 is C 1-6 bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with —O—, —CH(OR)—, —CH(SR)—, —CH(N(R) 2 )—, —C(O)—, —C(O)O—, —OC(O)—, —N(R)—, —C(O)N(R)—, —(R)NC(O)—, —OC(O)N(R)—, —(R)NC(O)O—, —N(R)C(O)N(R)—, —S—, —SO—, —SO 2 N(R)—, —(R)NSO 2 —, —C(S)—, —C(S)O—, —OC(S)—, —C(S)N(R)—, —(R)NC(S)—, or —(R)NC(S)N(R)—;

Ring A is optionally substituted phenyl;

Ring B is optionally substituted

R w is -L-Y;

L is a covalent bond or a bivalent C 1-8 saturated or unsaturated, straight or branched, hydrocarbon chain, wherein one, two, or three methylene units of L are optionally and independently replaced by cyclopropylene, —NR—, —N(R)C(O)—, —C(O)N(R)—, —N(R)SO 2 —, —SO 2 N(R)—, —O—, —C(O)—, —OC(O)—, —C(O)O—, —S—, —SO—, —SO 2 —, —C(═S)—, C(═NR)—, —N═N—, or —C(═N 2 )—;

Y is hydrogen, C 1-6 aliphatic optionally substituted with oxo, halogen, NO 2 , or CN, or a 3-10 membered monocyclic or bicyclic, saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein said ring is substituted with 1-4 R e groups;

each R e is independently selected from -Q-Z, oxo, NO 2 , halogen, CN, or a C 1-6 aliphatic optionally substituted with oxo, halogen, NO 2 , or CN;

Q is a covalent bond or a bivalent C 1-6 saturated or unsaturated, straight or branched, hydrocarbon chain, wherein one or two methylene units of Q are optionally and independently replaced by —N(R)—, —S—, —O—, —C(O)—, —OC(O)—, —C(O)O—, —SO—, or —SO 2 —, —N(R)C(O)—, —C(O)N(R)—, —N(R)SO 2 —, or —SO 2 N(R)—;

Z is hydrogen or C 1-6 aliphatic optionally substituted with oxo, halogen, NO 2 , or CN; and

each R is independently —H or optionally substituted —C 1-6 aliphatic.

2. The method of claim 1 , wherein L 1 is C 1-6 bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently replaced with —O—, —CH(OR)—, —CH(N(R) 2 )—, —C(O)—, —C(O)O—, —OC(O)—, —N(R)—, —C(O)N(R)—, —(R)NC(O)—, —OC(O)N(R)—, —(R)NC(O)O—, or —N(R)C(O)N(R)—.

3. The method of claim 2 , wherein L 1 is —CH 2 —.

4. The method of claim 1 , wherein Ring A is phenyl, optionally substituted 1-2 times by halogen, —CN, —NO 2 , or —C 1-6 aliphatic substituted 0-6 times by halogen, —CN, or —NO 2 .

5. The method of claim 4 , wherein Ring A is

R 1 is hydrogen, and R 7 is —C 1-6 aliphatic substituted 0-6 times by halogen.

6. The method of claim 1 , wherein Ring B is

7. The method of claim 6 , wherein Ring B is

8. The method of claim 1 , wherein R w is a

9. The method of claim 1 , wherein the compound is of Formula (IX) or (X):

10. The method of claim 9 , wherein the compound is of Formula (IXa), (IXb), or (Xa):

11. The method of claim 1 , wherein the compound is of Formula (XII):

12. The method of claim 11 , wherein the compound is of Formula (XIIa):

13. The method of claim 1 , wherein the compound is of Formula (XIII) or (XIV):

14. The method of claim 13 , wherein the compound is of Formula (XIIIa) or (XIIIb)

15. The method of claim 1 , wherein the compound is of Formula (XV):

16. The method of claim 15 , wherein the compound is of Formula (XVa) or (XVb):

17. The method of claim 1 , wherein the compound is selected from:

or a pharmaceutically acceptable salt thereof.

18. The method of claim 2 , wherein L 1 is C 1-6 bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently replaced with —N(R)—.

19. The method of claim 1 , wherein L 1 is —CH 2 —, —CH(CH 3 )—, —NH—CH 2 —, —NH—CH(CH 3 )—, —C(O)—NH—, or —N(CH 3 )—,

20. The method of claim 1 , wherein Ring A is

wherein each of R 1 and R 7 is independently —H, -halogen, —CN, —NO 2 , —C 1-6 aliphatic, or —O—C 1-6 aliphatic, wherein each of —C 1-6 aliphatic and —O—C 1-6 aliphatic is independently substituted 0, 1, 2, 3, 4, 5, or 6 times by -halogen, —CN, or —NO 2 .

21. The method of claim 1 , wherein Ring A is

22. The method of claim 1 , wherein:

L is —NRC(O)CH═CH—, —NRC(O)CH═CHCH 2 N(CH 3 )—, —NRC(O)CH═CHCH 2 O—, —CH 2 NRC(O)CH═CH—, —NRSO 2 CH═CH—, —NRSO 2 CH═CHCH 2 —, —NRC(O)(C═N 2 )—, —NRC(O)(C═N 2 )C(O)—, —NRC(O)CH═CHCH 2 N(CH 3 )—, —NRSO 2 CH═CH—, —NRSO 2 CH═CHCH 2 —, —NRC(O)CH═CHCH 2 O—, —NRC(O)C(═CH 2 )CH 2 —, —CH 2 NRC(O)—, —CH 2 NRC(O)CH═CH—, —CH 2 CH 2 NRC(O)—, or —CH 2 NRC(O)cyclopropylene-; and

Y is hydrogen or C 1-6 aliphatic optionally substituted with oxo, halogen, NO 2 , or CN.

23. The method of claim 1 , wherein:

L is a covalent bond;

Y is a partially unsaturated 4-6 membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Re groups; and

each Re is independently selected from oxo, NO 2 , halogen, and CN.

24. The method of claim 1 , wherein the cancer is associated with increased TEAD expression or increased TEAD activity.

25. The method of claim 1 , wherein the cancer is associated with increased TEAD1 expression or increased TEAD1 activity; increased TEAD2 expression or increased TEAD2 activity; increased TEAD3 expression or increased TEAD3 activity; increased TEAD4 expression or increased TEAD4 activity; or any combination thereof.

26. The method of claim 1 , wherein the cancer is a cancer in which YAP is localized in the nucleus of the cancer cells.

27. The method of claim 1 , wherein the cancer is lung cancer, thyroid cancer, ovarian cancer, colorectal cancer, prostate cancer, cancer of the pancreas, cancer of the esophagus, liver cancer, breast cancer, skin cancer, mesothelioma or leukemia.